Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tebentafusp in Uveal Melanoma: NCT06246149 Clinical Landscape Report 2026
16 October 2026
NCT06246149 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MGC-026 in Sarcoma: NCT06242470 Clinical Landscape Report 2026
16 October 2026
NCT06242470 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fianlimab/Cemiplimab in Melanoma: NCT06246916 Clinical Landscape Report 2026
16 October 2026
NCT06246916 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AB-2100 in Renal Cell Carcinoma: NCT06245915 Clinical Landscape Report 2026
16 October 2026
NCT06245915 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclosporine in DNA Repair-Deficiency Disorders: NCT06246786 Clinical Landscape Report 2026
16 October 2026
NCT06246786 clinical landscape for DNA Repair-Deficiency Disorders: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Locally advanced breast cancer: NCT06246968 Clinical Landscape Report 2026
16 October 2026
NCT06246968 clinical landscape for Locally advanced breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Triple Negative Breast Cancer: NCT06245889 Clinical Landscape Report 2026
16 October 2026
NCT06245889 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CS-23546 in Extranodal NK-T-Cell Lymphoma: NCT06245122 Clinical Landscape Report 2026
16 October 2026
NCT06245122 clinical landscape for Extranodal NK-T-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mosunetuzumab in High grade B-cell lymphoma: NCT06249191 Clinical Landscape Report 2026
16 October 2026
NCT06249191 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Diffuse Large B-Cell Lymphoma: NCT06247540 Clinical Landscape Report 2026
16 October 2026
NCT06247540 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Uveal Melanoma: NCT06249048 Clinical Landscape Report 2026
16 October 2026
NCT06249048 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Mantle-Cell Lymphoma: NCT06251180 Clinical Landscape Report 2026
16 October 2026
NCT06251180 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.